ADDING PERTUZUMAB IN NEOADJUVANT TREATMENT OF PATIENTS WITH HER2+ BREAST CANCER IN SPAIN: A COST OFFSETS STUDY

被引：0
|
作者：
Albanell, J. [1 ]
Ciruelos, E. [2 ]
Colomer, R. [3 ]
De la Haba, J. [4 ]
Martin, M. [5 ]
De Salas-Cansado, M. [6 ]
Munoz-Molina, B. [6 ]
Tournier, C. [7 ]
Thuresson, P. [7 ]
Schleich, W. [7 ]
机构：
[1] Hosp Mar, Barcelona, Spain
[2] Hosp Univ 12 de Octubre, Madrid, Spain
[3] Hosp Univ La Princesa, Madrid, Spain
[4] Hosp Univ Reina Sofia, Cordoba, Spain
[5] Hosp Univ Gregorio Maranon, Madrid, Spain
[6] Roche Farma SA, Madrid, Spain
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2015年 / 117卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
C070
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of adding neoadjuvant chemotherapy with pertuzumab, in patients with HER2+breast cancer in Spain
    Abanell, J.
    Ciruelos, E.
    De la Haba, J.
    Martin, M.
    Munoz-Molina, B.
    De Salas-Cansado, M.
    Colomer, R.
    [J]. CANCER RESEARCH, 2017, 77
  • [2] Pertuzumab in the Treatment of HER2+ Breast Cancer
    Jhaveri, Komal
    Esteva, Francisco J.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 (04): : 591 - 598
  • [3] The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data
    Andreia Borges
    Filipa Pereira
    Patrícia Redondo
    Luís Antunes
    Cláudia Vieira
    Pedro Antunes
    Maria José Bento
    Susana Sousa
    José Machado Lopes
    Francisco Rocha-Gonçalves
    Joaquim Abreu de Sousa
    Deolinda Sousa Pereira
    Marina Borges
    [J]. Health Economics Review, 11
  • [4] COST-ESTIMATE OF ADDING NEOADJUVANT PERTUZUMAB FOR THE TREATMENT OF HER2+BREAST CANCER IN AN INSTITUTION IN PORTUGAL
    Borges, A.
    Pereira, F.
    Redondo, P.
    Antunes, L.
    Vieira, C.
    Antunes, P.
    Bento, M. J.
    Sousa, S.
    Machado Lopes, J.
    Goncalves, F. R.
    Abreu de Sousa, J.
    Pereira, D.
    Borges, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S475 - S475
  • [5] New directions in the neoadjuvant treatment of HER2+ breast cancer
    Hobbs, Evthokia A.
    Hurvitz, Sara A.
    [J]. BREAST CANCER MANAGEMENT, 2015, 4 (04) : 223 - 234
  • [6] ECONOMIC IMPACT OF THE INCLUSION OF PERTUZUMAB FOR THE TREATMENT OF METASTATIC BREAST CANCER HER2+
    Nazco, G.
    Gutierrez, F.
    Bullejos, M.
    Vina, M.
    Gonzalez, I
    Valcarcel, C.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A638 - A638
  • [7] COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN
    Colomer, R.
    Ciruelos, E.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Albanell, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A740 - A740
  • [8] Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancer
    Abraham, Jame
    [J]. JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (03): : 84 - 86
  • [9] Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer
    Angelica L. Quartino
    Hanbin Li
    Jin Y. Jin
    D. Russell Wada
    Mark C. Benyunes
    Virginia McNally
    Lucia Viganò
    Ihsan Nijem
    Bert L. Lum
    Amit Garg
    [J]. Cancer Chemotherapy and Pharmacology, 2017, 79 : 353 - 361
  • [10] Cardiotoxicity of the HER2 dimerisation inhibitor pertuzumab in patients with breast cancer HER2+: A systematic review
    Olivares Hernandez, A.
    Escala Cornejo, R. A.
    Toribio Garcia, I.
    Figuero Perez, L.
    Vidal Tocino, R.
    Miramontes Gonzalez, J. P.
    Martin Garcia, G.
    Seijas Tamayo, R.
    Cruz-Hernandez, J. J.
    Rodriguez Sanchez, C. A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1240 - S1240
12345